Summary of Significant Accounting Policies - Schedule of Financial Assets and Liabilities Measured and Recognized at Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Assets:
Money market funds	$ 11,281	$ 47,567
Acquisition rights of Enalare Therapeutics, Inc.	8,125	8,125
Liability:
Forward Liability		4,063
Investment in Syros Pharmaceuticals, Inc. ("Syros")
Assets:
Investments	1,380	1,573
Investment in Enalare Therapeutics, Inc.
Assets:
Investments	16,952	8,438
Acquisition rights of Enalare Therapeutics, Inc.	8,125	8,125
Liability:
Forward Liability	0	4,063
Level 1
Assets:
Money market funds	11,281	47,567
Acquisition rights of Enalare Therapeutics, Inc.	0	0
Liability:
Forward Liability		0
Level 1 | Investment in Syros Pharmaceuticals, Inc. ("Syros")
Assets:
Investments	1,380	1,573
Level 1 | Investment in Enalare Therapeutics, Inc.
Assets:
Investments	0	0
Level 2
Assets:
Money market funds	0	0
Acquisition rights of Enalare Therapeutics, Inc.	0	0
Liability:
Forward Liability		0
Level 2 | Investment in Syros Pharmaceuticals, Inc. ("Syros")
Assets:
Investments	0	0
Level 2 | Investment in Enalare Therapeutics, Inc.
Assets:
Investments	0	0
Level 3
Assets:
Money market funds	0	0
Acquisition rights of Enalare Therapeutics, Inc.	8,125	8,125
Liability:
Forward Liability		4,063
Level 3 | Investment in Syros Pharmaceuticals, Inc. ("Syros")
Assets:
Investments	0	0
Level 3 | Investment in Enalare Therapeutics, Inc.
Assets:
Investments	$ 16,952	$ 8,438